Is This Iran's Opening Act or Curtain Call?
Save
This is Bloomberg Opinion Today, a caregiver of Bloomberg Opinion's opinions. Sign up here.
There are many things I could ask at the beginning of this newsletter. Why is President Donald Trump ranting about the 'N word'? How come my TikTok feed is flooded with absurd World War 3 videos? Should we be worried that there's an Instagram account dedicated to the eyebrow of Trump's 22-year-old anti terrorism chief?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
33 minutes ago
- Fox News
Flashback: NYC mayoral candidate Zohran Mamdani vowed to arrest Netanyahu if he visited the city
New York City Democratic mayoral candidate Zohran Mamdani, who declared victory in the Democratic primary for mayor on Tuesday, said previously that he would arrest Israeli Prime Minister Benjamin Netanyahu if he ever visited the city. In December, former MSNBC host Mehdi Hasan, now editor-in-chief and CEO of Zeteo, asked Mamdani, "Mayor Mamdani, would you welcome Prime Minister Netanyahu to New York City for the — for whatever he comes for, given the U.S. is not a signatory to the ICC, so he can travel to the U.S., unlike a lot of other countries? Would a Mayor Mamdani welcome Benjamin Netanyahu to this city?" Mamdani, a 33-year-old state assembly member from Queens who was born and raised in Uganda, told Hasan, "No. As mayor, New York City would arrest Benjamin Netanyahu. This is a city that our values are in line with international law. It's time that our actions are also." Hasan pressed Mamdani, asking him if he would still arrest Netanyahu even though Israel is not part of the International Criminal Court (ICC), an organization that reviews global matters like war crimes and genocide. In February, President Donald Trump signed an executive order sanctioning the ICC in response to its May 2024 arrest warrant for Netanyahu. Mamdani told Hasan that, "It's time that we actually step up and make clear what we are willing to do to showcase the leadership that is sorely missing in the federal administration." In a speech earlier this month at the B'nai Jeshurun synagogue in Manhattan, Mamdani appeared to double down on his position that he would arrest Netanyahu as mayor. "My answer is the same whether we are speaking about Vladimir Putin or Netanyahu. I think that this should be a city that is in compliance with international law," Mamdani said. "And we have seen other countries across the world that are signatories of the ICC [International Criminal Court] that they would honor that same request, being Canada or other countries in Europe, and their honoring of it meant that Netanyahu did not travel there." During an event in May, Mamdani reportedly said that he believes "that Israel has a right to exist with equal rights for all," and recently told Late Night host Stephen Colbert that, "Yes, like all nations, I believe it has a right to exist." He has been linked to anti-Israel activism, according to a report by Canary Mission, a watchdog group that tracks antisemitism, which said that Mamdani regularly attends New York City's anti-Israel protests, and that he took part in protests against Israel days after the Hamas' Oct. 7, 2023, terror attack that killed 1,200 Israelis. The report also noted that Mamdani's father, Mahmood Mamdani, is an anthropology professor at Columbia University, which has been a hub of anti-Israel protests since the Oct. 7, 2023, terrorist attack. It also highlights that Mamdani's filmmaker mother, Mira Nair, signed an open letter calling for Israeli actress Gal Gadot to be removed from presenting at the 2025 Academy Awards. During his victory speech on Tuesday, Mamdani said that he envisions a New York City "where the mayor will use their power to reject Donald Trump's fascism, to stop mass ICE agents from deporting our neighbors and to govern our city as a model for the Democratic Party." Fox News Digital reached out to Mamdani for comment, but did not immediately receive a response.
Los Angeles Times
34 minutes ago
- Los Angeles Times
Court orders Trump administration to facilitate another deported man's return from El Salvador
WASHINGTON — A federal appeals court in New York on Tuesday ordered the Trump administration to facilitate the return of a man who was deported to El Salvador roughly 30 minutes after the court suspended an order to remove him from the U.S. The ruling in Jordin Alexander Melgar-Salmeron's case marks at least the fourth time this year that President Trump's administration has been ordered to facilitate the return of somebody mistakenly deported. The government said 'a confluence of administrative errors' led to Melgar-Salmeron's deportation on May 8, according to the decision by a three-judge panel from the 2nd U.S. Circuit Court of Appeals. The panel said administration officials must facilitate his return to the U.S. 'as soon as possible.' The judges gave them a week to identify his current physical location and custodial status and to specify what steps they will take to facilitate his return. Kilmar Abrego Garcia, whose mistaken deportation in March became a flashpoint in Trump's immigration crackdown, was returned from El Salvador this month to face human smuggling charges in Tennessee. In April, a Trump-nominated judge in Maryland ordered his administration to facilitate the return of a man who was deported to El Salvador in March despite having a pending asylum application. U.S. District Judge Stephanie Gallagher ruled that the government violated a 2019 settlement agreement when it deported the 20-year-old man, a Venezuelan native identified only as Cristian in court papers. And in May, another judge ordered the administration to facilitate the return of a Guatemalan man whom it deported to Mexico despite his fears of being harmed there. U.S. District Judge Brian Murphy found that the removal of the man, who is gay, likely 'lacked any semblance of due process.' Kunzelman writes for the Associated Press.
Yahoo
35 minutes ago
- Yahoo
China is a real threat to US biotech innovation: EY life science expert
China's growing biotech prowess has become a real threat to the industry in the US in recent years. Moves by the Trump administration could weaken the US market further, according to several experts watching the deals flowing into China, which amounted $30 billion in 2024 and are already more than half that total in mid-2025. EY life sciences leader Arda Ural is among those watching and said that China is no longer the land of generics and active pharmaceutical ingredients (APIs) used by the rest of the world. China has long been known as a "me too" producer — that is, a manufacturer of generics — as well as a source of APIs. But China is showing its might as it clinches more licensing deals for drugs developed domestically and increases clinical trials being conducted in the country. "The numbers are pretty compelling," Ural told Yahoo Finance. "A couple of years ago, we had pretty much no deals, or maybe under $1 billion in 2016. As of last year, there were $30 billion of licensing deals of Chinese assets into the US." But this didn't happen overnight. The Chinese Communist Party laid out a roadmap in 2015 that included investing in and growing the country's biotech sector. Ten years later, that is coming to fruition, Ural said. "That journey now is taking them upstream to more advanced innovation. Probably, we still have not seen first-in-class, but clearly they are going for best-in-class," Ural said. US companies buying or licensing products from China include a due diligence process, which can involve head-to-head comparisons to existing drugs or repeating clinical trials to ensure the data and efficacy results are accurate. This has helped ease concerns about intellectual property theft of US products, as well as concerns about data integrity in China. The prior doubts spurred the introduction of the Biosecure Act in Congress in 2023, which would prevent any entity receiving federal funds from using biotech equipment or services from "companies of concern." That bill has stalled in Congress. Meanwhile, the life sciences community continues to increase its interest in China. Companies like WuXi Biologics (WXXWY), WuXi AppTec (WUXAY), and BGI (formerly Beijing Genomics Institute) are among those under the spotlight. And during the pandemic, companies like CanSino ( which developed a vaccine, came into view. Now, with cuts to research funding in the US to the National Institutes of Health (NIH), as well as the loss of Food and Drug Administration staff, insiders are warning that China could fill the gaps and scoop up talent from the US. "The US still has the capacity to invest, but it is not, potentially, the only game in town," Ural said. He explained that China is still early in its journey, and while it does have government funding and Western-educated doctors and researchers, it doesn't have the type of firepower of US capital markets. "That is where they are lacking. There is no IPO market comparable to Western markets, there is no M&A exit strategy ... so that's the opportunity for them to come up," Ural said. A majority of the deals so far are US-based companies buying early-stage assets from Chinese company pipelines, bringing them to the US to validate and then produce and sell. At the same time, the US-based biotech industry has seen a slowdown in investment and IPO activity, and the NIH funding cuts by the Trump administration are exacerbating the dry spell. China's growth is also adding to the pressure since China is known for making things cheaper and faster than Western countries. Ural said that's why the partnership with US-based firms is a "winning strategy" for the overall industry. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices
